# Evaluating the Safety and Efficacy of Oral Lenvatinib in Medullary and Iodine-131 Refractory, Unresectable Differentiated Thyroid Cancers, Stratified by Histology

> **NCT00784303** · PHASE2 · COMPLETED · sponsor: **Eisai Inc.** · enrollment: 117 (actual)

## Conditions studied

- Thyroid Cancer

## Interventions

- **DRUG:** Lenvatinib (DTC Cohort)
- **DRUG:** Lenvatinib (MTC Cohort)

## Key facts

- **NCT ID:** NCT00784303
- **Lead sponsor:** Eisai Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-11-06
- **Primary completion:** 2011-04-11
- **Final completion:** 2019-03-29
- **Target enrollment:** 117 (ACTUAL)
- **Last updated:** 2020-04-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00784303

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00784303, "Evaluating the Safety and Efficacy of Oral Lenvatinib in Medullary and Iodine-131 Refractory, Unresectable Differentiated Thyroid Cancers, Stratified by Histology". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT00784303. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*